Metabolic syndrome (MetS) is characterized by accumulation of visceral fat associated with the clustering of metabolic and pathophysiological cardiovascular risk factors; impaired glucose tolerance or type-2 diabetes mellitus (T2DM), dyslipidemia and hypertension [1], and has a strong impact on the global incidence of the life-threatening cardiovascular disease such as stroke and myocardial infarction [2, 3] . The prevalence of MetS is rapidly increasing worldwide not only in industrialized countries but also in developing countries associated with a change in the lifestyle including the increase in food intake and the decrease Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome abstract. Type 2 diabetes mellitus (T2DM) associated with metabolic syndrome (MetS) represents a high risk of cardiovascular disease. We compared the effect of early intervention with pioglitazone versus voglibose on physical and metabolic profiles and serum adiponectin level in patients with T2DM associated with MetS. Sixty patients who were diagnosed for the first time as T2DM associated with MetS were analyzed for insulin sensitivity, lipid profile, serum adiponectin and systemic inflammation. Those patients were randomly assigned to oral pioglitazone group (n = 30) or voglibose group (n = 30) in addition to conventional diet and exercise training. Body mass index and waist circumference did not change in the pioglitazone group, whereas these physical parameters significantly decreased in the voglibose group during a 6-month follow-up period. However, glycosylated hemoglobin, fasting plasma glucose, and HOMA-IR more significantly decreased in the pioglitazone group. The level of serum adiponectin especially high-molecular weight adiponectin markedly increased in the pioglitazone group. Moreover, high sensitive CRP significantly decreased only in the pioglitazone group. These results suggest that voglibose is superior in improving obesity, while pioglitazone is superior in ameliorating insulin sensitivity and increasing serum adiponectin in patients with an early stage of T2DM associated with MetS.
in exercise.
Therapeutic opportunities for MetS comprise lifestyle modification in conjunction with drug treatment for the MetS-associated complications. Caloric restriction (CR) and regular exercise greatly reduce waist circumference and body mass index (BMI), lower blood pressure and improve lipid profile. Lifestyle modification has been shown to prevent T2DM development. Nevertheless, appropriate treatment of cardiovascular risk factors in MetS often requires pharmacologic interventions against T2DM with insulin-sensitizing agents, such as thiazolidinediones (TZDs) and metformin, or
This study was conducted according to the principles expressed in the Declaration of Helsinki. Informed consent was obtained from each subject after full explanation of the purpose, nature, and risk of all procedures used. The protocol was approved by the ethical review committee at Kansai Medical University, Moriguchi City, Japan.
Measurements
Systolic blood pressure and diastolic blood pressure were measured with automatic electronic sphygmomanometer (HEM-907; Omron, Tokyo, Japan), twice in the sitting position after resting for at least 5 minutes. Height, weight, BMI and waist circumference were measured at the time of physical examination. The value of glycosylated hemoglobin A1c (HbA1c) was estimated as an NGSP equivalent value (%) calculated by the formula HbA1c=HbA1c (JDS) (%) + 0.4 % considering the relational expression of HbA1c (JDS) (%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP) [10] . Fasting plasma glucose, serum TGs, serum HDLcholesterol, serum low-density lipoprotein (LDL)cholesterol, serum insulin, serum adiponectin, serum HMW and total adiponectin, and serum high sensitive C-reactive protein (hsCRP) level were measured in the morning after an overnight fasting. Adiponectin was measured according to the method as described previously [11] . True waist circumference was measured midway between the tenth rib and the iliac crest with the subjects in the standing position, recorded at the end of a gentle expiration. Plasma glucose was measured by a glucose oxidase method using GA-1152 (Arkrey, Kyoto, Japan). HbA1c was measured by a high performance liquid chromatography method using HLC-723G8 (Tosoh, Tokyo, Japan). Plasma lipids were assayed by routine automated laboratory methods using COLESTEST (Shimizu Medical, Tokyo, Japan). Serum insulin concentration was measured by the electrochemiluminescence immunoassay using a commercially available kit MODULAR ANALYTICS E170 (Roche Diagnostics GmbH, Mannheim, Germany). Plasma adiponectin concentration was measured as described elsewhere [12] . Serum hsCRP was measured by an ultra high sensitivity latex turbidimetric immunoassay method using CRP Latex X2 (Denka Seiken, Tokyo, Japan). Homeostasis model assessment of insulin resistance (HOMA-IR), an insulin resistance index, was calculated as described elsewhere [13] .
α-glucosidase inhibitors.
The beneficial effect of TZDs is attributed to activation of peroxisome proliferator activated receptor (PPAR)-γ in the adipose tissue and resultant generation of adiponectin [4, 5] , which is known to provide favorable metabolic effects, i.e. greater insulin sensitivity, reduced visceral adipose mass, reduced plasma triglycerides (TGs), and increased high-density lipoprotein (HDL)-cholesterol [6] . On the other hand, α-glucosidase inhibitors have shown to prevent the development of T2DM in people with impaired glucose tolerance (IGT) by inhibiting postprandial hyperglycemia [7] . In addition, an α-glucosidase inhibitor voglibose, can reduce the development of T2DM in highrisk Japanese individuals with IGT [8] . Therefore, both TZDs and α-glucosidase inhibitors are promising anti-diabetic drugs against cardiovascular risk factors in MetS. The purpose of the present study was to compare the effect of pioglitazone, the most commonly employed TZDs, versus voglibose on metabolic profiles and adiponectin in patients with T2DM associated with MetS.
Subjects and Methods

Patients
Between April 2007 and February 2010, 62 patients who were diagnosed for the first time as T2DM associated with MetS were enrolled in the present study. All subjects meet the criteria of T2DM raised by the Japanese Diabetes Society (Treatment Guide for Diabetes 2008-2009). MetS was diagnosed to subjects having one or more of the following criteria for MetS [9] ; serum TGs level ≥ 150 mg/dl, serum HDLcholesterol level < 40 mg/dl, systolic blood pressure ≥ 130 mmHg and / or diastolic blood pressure ≥ 85 mmHg besides waist circumference ≥ 85 cm for male and ≥ 90 cm for female. Those patients were randomly assigned to oral pioglitazone group (n = 31) or matching voglibose group (n = 31) in addition to diet and exercise training during a 6-month follow-up period according to the VICTORY Study [8] . The pioglitazone group and voglibose group of patients received pioglitazone at 30 mg daily and voglibose at 0.9 mg daily for 6 months, respectively. One patient in the pioglitazone group and one patient in the voglibose group were eliminated from the study because of heart failure and intractable diarrhea, respectively. Thus, the data from 60 patients (n = 30 in each group) were analyzed. kg/m 2 ; voglibose: -1.2 ± 1.1 kg/m 2 ; p < 0.05 vs. baseline). This was associated with a significant decrease in waist circumference in the voglibose group (pioglitazone: 0 ± 5.7 cm; voglibose: -3 ± 5 cm; p < 0.05 vs. baseline). Systolic and diastolic blood pressures significantly decreased in both groups without a significant intergroup difference.
Significant improvement of HbA1c was observed at 6-month follow-up in both groups (pioglitazone: -0.3 ± 0.5 %; voglibose: -0.2 ± 0.6 %, p < 0.05 vs. baseline in both groups). However, HbA1c was significantly (p < 0.02) less in the piogritazone group compared to the voglibose group. Fasting glucose significantly decreased in the pioglitazone group (pioglitazone: -22 ± 40 mg/dL, p = 0.002), while it did not significantly decrease in the voglibose group (-6 ± 29 mg/dL, p = 0.274). Accordingly, the fasting glucose level was significantly (p = 0.028) less in the pioglitazone group compared to the voglibose group. Fasting serum insulin significantly decreased in the pioglitazone group (-4.7 ± 10.2 μU/mL, p = 0.013), while it did not significantly change in the voglibose group (-6 ± 29 μU/ mL, p = 0.351). Similarly, HOMA-IR significantly
Statistical analysis
All analyses were performed with appropriate nonparametrical methods. Treatment groups were compared at baseline by a Wilcoxon rank sum test for continuous variables and chi-square for categorical variables. The difference between treatment groups was assessed by using t test statics for the hypothesis that treatment group is a relevant factor in the model. Continuous variables are expressed as mean ± SD. All p values < 0.05 were interpreted as statistically significant.
Results
Demographic patients' characteristics of 60 subjects who completed a 6-month follow-up are presented in Table 1 . There were no statistically significant differences in any baseline physical and metabolic characteristics between the groups treated with pioglitazone and voglibose. The use of drugs for anti-hypertension and anti-dyslipidemia was similar in both groups.
Changes in the physical and metabolic parameters are shown in Table 2 . BMI significantly decreased only in the voglibose group (pioglitazone: -0.3 ± 1.17 
Discussion
We compared the change in physical and metabolic profiles after administration with pioglitazone versus voglibose in patients who were diagnosed for the first time as T2DM associated with MetS. Although this study was not placebo-controlled, and the sample size was small, there were several salient differences in these profiles. BMI and waist circumference did not change in the pioglitazone group, whereas these physical parameters significantly decreased in the voglibose group during a 6-month follow-up period. Because these groups of patients equally received diet and physical therapy, these results suggest that voglibose is superior in improving obesity compared to pioglitazone. It has been demonstrated that an α-glucosidase inhibitor, acarbose, decreases waist circumference in human obese subjects associated with T2DM [14] , and this effect is attributed to the reduction of visceral fat [15] . Our finding using voglibose supports the antivisceral obesity effect of α-glucosidase inhibitors. Although we measured waist circumference as a surrogate marker of visceral obesity, waist circumference is not an accurate indicator for visceral adiposity. It has been demonstrated that TZDs cause a major redistribution of body fat with a decrease in visceral fat content [16] . Thus, it is possible that abdominal subcutaneous fat but not visceral fat was increased by pioglitazone tratement. Analysis of abdominal fat content by com-decreased in the pioglitazone group (-2.7 ± 6.1, p = 0.037), while it remained unchanged in the voglibose group (-0.1 ± 8.1, p = 0.735). LDL-cholesterol significantly decreased in the pioglitazone group (-15 ± 26 mg/dL, p = 0.048), while it remained unchanged in the voglibose group (-2 ± 31 mg/dL, p = 0.710). Subanalysis of LDL-cholesterol data showed that the LDL-cholesterol level significantly decreased in the pioglitazone group of patients who had been receiving statins (127 ± 23 mg/dL from the baseline to 102 ± 29 mg/dL at 6 month) compared to those without statins (130 ± 41 mg/dL from the baseline to 128 ± 19 mg/ dL at 6 month). LDL-cholesterol level did not significantly change in the voglibose group of patients with statins (135 ± 63 mg/dL from the baseline to 133 ± 51 mg/dL at 6 month) or without statins (131 ± 44 mg/ dL from the baseline to 130 ± 35 mg/dL at 6 month). HDL-cholesterol significantly increased in the pioglitazone group (+4 ± 11 mg/dL, p = 0.013), while it did not increase in the voglibose group (+1 ± 8 mg/dL, p = 0.794). The TGs level significantly decreased in both groups with a trend being lower in the voglibose group (p = 0.091). In both groups, a significant increment of total and HMW adiponectin was observed (pioglitazone: +8.5 ± 12.2μg/mL and +6.1 ± 10.9 μg/mL; voglibose: +0.9 ± 1.5 μg/mL and +0.5 ± 0.9 μg/mL; p < 0.05 vs. baseline in both groups). However, total and HMW adiponectin was significantly increased in the pioglitazone group compared to the voglibose group. present study was too short to evaluate macrovascular endopoints. Further research is warranted to elucidate the exact mechanism of action by which adiponectin confers the anti-atherosclerotic effect. Interestingly, pioglitazone significantly decreased LDL-cholesterol in the presence of statins. Theoretically, improvement of insulin sensitivity and reduction of TGs are associated with a decrease in small dense LDL particles and an increase in HDL and LDLcholesterol. Leonhardt et al. [27] reported that pioglitazone alone or in combination with simvastatin had no significant effect on LDL-cholesterol level. We administered pioglitazone in patients who continued statins (pitavastatin, rosuvastatin or atorvastatin) and other lipid-altering therapies maintaining stable serum LDLcholesterol level. Although the number of patients who administered statins was small, there was no tendency to show a difference in a drug effect between these statins on LDL-cholesterol level in combination with pioglitazone. To the best of our knowledge, there has been no report which analyzed the change in the LDLcholesterol level in patients with T2DM and high LDLcholesterolemia. Whatever the mechanism of increase in the efficacy of statins after administration of pioglitazone, the statin-sensitizing effect of pioglitazone in subjects complicated with high-LDL cholesterolemia may be favorable in preventing high dose statin-induced side-effects such as rhabdomyolysis and reducing medical cost.
The effect of voglibose on physical and metabolic parameters appears to be attributed to the improvement of obesity and reduction of visceral fat. Voglibose is a CR-mimetic drug. CR primary affects energy stores in visceral adipose tissue [28] . Indeed, a substantial improvement in all aspects of MetS with only a moderate degree of weight loss by CR has been observed in a randomized clinical trial [29] . The favorable effect of adipose tissue reduction could be due to increased production of adiponectin and decreased production of proinflammatory adipocytokines such as tumor necrosis factor-α, interleukin-6, monocyte chemoattractant protein-1, plasminogen activator inhibitor-1 [20, 30, 31] . Imbalance between adiponectin and pro-inflammatory cytokines is responsible for oxidative stress especially to endothelial cells and underlies the pathogenesis of the obesity-associated insulin resistance, T2DM, dyslipidemia and hypertension. We found that voglibose improved visceral obesity, reduced HbA1c and serum TGs level and modestly increased total and HMW adi-puted tomography will be necessary to evaluate actual visceral fat volumes.
The present study demonstrated that systolic and diastolic blood pressures similarly decreased in both groups. This decrease in blood pressure is at least in part attributed to the improvement of lifestyle. In addition, the reduction of visceral adipose tissue may also be an important factor in the blood pressure lowering effect of voglibose. We found that HbA1c, fasting plasma glucose, and HOMA-IR more significantly decreased in the pioglitazone group. These results suggest that pioglitazone is superior in ameliorating insulin sensitivity compared to voglibose. The previous study [17] demonstrated that pioglitazone was capable of improving insulin sensitivity in patients with T2DM without a change in intra-abdominal fat, and the improved insulin sensitivity was correlated with an increase in serum adiponectin level. The present study also demonstrated that pioglitazone is superior in increasing the level of serum adiponectin especially HMW adiponectin. A similar effect of pioglitazone on the serum HMW adiopnectin level has already been reported by Aso et al. who demonstrated that low-dose pioglitazone significantly increased HMW adiponectin and improved glycemic control in patients with advanced T2DM [18] . It is now apparent that adiponectin exerts diverse effects on glucose and lipid metabolism, thereby improving insulin sensitivity and lowering TGs [19] .
Adiponectin is also known to act as an anti-inflammatory molecule [20] . The present study indeed demonstrated that pioglitazone-induced increase in adiponectin was associated with a significant decrease in hsCRP, which has been implicated in a valuable marker for atherosclerosis [21] [22] [23] . This anti-inflammatory effect may play a crucial role in preventing the development of atherosclerosis and cardiovascular disease. It has been demonstrated that in a large, placebo-controlled, outcome study in secondary prevention, PROactive study, the use of pioglitazone in addition to an existing optimized macrovascular risk management resulted in a significant reduction of macrovascular endpoints within a short observation period that was comparable to the effect of statins and angiotensin-converting enzyme inhibitors in other trials [24] . In addition, the efficacy of TZDs in preventing atherosclerosis in patients with T2DM has been confirmed by subsequent clinical trials [25] . However, a recent study lack of association between adiponectin levels and atherosclerosis in preclinical rodent models [26] . A follow-up period in our pioglitazone dissociated the blood-pressure response to salt and abolished salt sensitivity in salt-sensitive individuals. These effects cause fluid retention and may contribute to the increased incidence of congestive heart failure with TZDs. In the present study, we encountered one patient who discontinued pioglitazone due to overt heart failure. However, because surrogate end points used to indicate fluid retention (body weight, hematocrit, total protein, and albumin) may not change [35] , careful follow-up is necessary not to overlook latent heart failure in patients receiving pioglitazone.
In conclusion, our present data suggest that voglibose is superior in improving obesity, while pioglitazone is superior in ameliorating insulin sensitivity in patients with an early stage of T2DM complicated by MetS. In addition, pioglitazone exerted more favorable effects on serum adiponectin and systemic inflammation at 6-month follow-up. Long term follow-up would unmask the ultimate superiority of these drugs with respect to the development of T2DM and atherosclerotic cardiovascular disease.
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ponectin, suggesting that the decrease in visceral fat stimulated the production of adiponectin. A similar effect on serum adiponectin level has been observed in other α-glucosidase inhibitors, miglitol and acarbose, in patients with T2DM [32, 33] . Therefore, it is possible that voglibose could improve insulin resistance as has been proposed by Satoh et al. [34] . However, insulin resistance and systemic inflammation were not significantly improved by administration of voglibose during a 6-month follow-up period. The question as to whether the inferiority of voglibose in improving insulin resistance and systemic inflammation is due to lower adiponectin level compared to pioglitazone remains unknown at present. Longer follow-up may be necessary to improve insulin resistance and systemic inflammation in the voglibose group.
Pioglitazone and other TZDs are associated with fluid retention and edema that may exacerbate existing or developing congestive heart failure [35] . Pioglitazone increases diurnal proximal sodium retention in diabetic and hypertensive individuals [36] . Pioglitazone was associated with a rapid increase in body weight and an increase in diurnal proximal sodium reabsorption, without any changes in renal hemodynamics or in the modulation of the renin-angiotensin aldosterone system to changes in salt intake. In spite of sodium retention,
